Last week the Committee on Energy and Commerce sent letters to Amphastar Pharmaceuticals, Momenta Pharmaceuticals, Siegfried USA, Inc., Sagent Pharmaceutical, APP Pharmaceuticals, Sanofi Aventis, Drug Source Company LLC, Global Pharma Sourcing LLC, Pacific Rainbow International, and Sandoz.
The move comes after documents from the US FDA indicated that the list of firms have information related to the case, in which 100 US citizens died because of the adulteration of the popular blood-thinning drug’s supplies.
The letter, signed by Committee Chairman Fred Upton and members, states: “It is important to determine how the adulteration happened so that industry and government can take more effective proactive measures to reduce the risk of such adulteration in the future.”
view the letter here: http://republicans.energycommerce.house.gov/Media/file/Letters/062911%20Letter%20to%20John%20Ducker.pdf
View the announcement here: http://energycommerce.house.gov/news/PRArticle.aspx?NewsID=8768